Showing results (81-90 of 115) with videos related to
Sort By:
Pageof 12
Cardio-Oncology (London, England)|July 4, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trialLisa B Leypoldt, Linlin Guo, Britta Besemer, et al.Blood|May 29, 2016
Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemiaRachel Thijssen, Johanna Ter Burg, Brett Garrick, et al.Cell Reports. Medicine|February 10, 2024
An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCLLars Fabian Prinz, Tobias Riet, Daniel Felix Neureuther, et al.Journal of Cancer Research and Clinical Oncology|November 14, 2024
A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an actionable sensitivity to immune checkpoint blockadeOlta Ibruli, France Rose, Filippo Beleggia, et al.Cancer Research|August 10, 2017
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA DamageLukas Perkhofer, Anna Schmitt, Maria Carolina Romero Carrasco, et al.NPJ Digital Medicine|August 19, 2023
Predicting HPV association using deep learning and regular H&E stains allows granular stratification of oropharyngeal cancer patientsSebastian Klein, Nora Wuerdemann, Imke Demers, et al.Haematologica|November 9, 2023
Autologous-allogeneic <i>versus</i> autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II studyNicolaus Kröger, Gerald Wulf, Ute Hegenbart, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple MyelomaLisa B Leypoldt, Diana Tichy, Britta Besemer, et al.Cell Reports|October 26, 2018
The Cdkn1a<sup>SUPER</sup> Mouse as a Tool to Study p53-Mediated Tumor SuppressionAlessandro Torgovnick, Jan Michel Heger, Vasiliki Liaki, et al.Journal of Hematology & Oncology|May 21, 2026
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysisNico Gagelmann, Hermann Einsele, Sarah Flossdorf, et al.Pageof 12